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Targeting the EGF receptor in ovarian cancer with the tyrosine
kinase inhibitor ZD 1839 (‘Iressa’)
JM Sewell1, KG Macleod1, A Ritchie1, JF Smyth1 and SP Langdon*,1
1Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh EH4 2XU, UK
The modulating effects of the orally active epidermal growth factor receptor-specific tyrosine kinase inhibitor ZD 1839
(‘Iressa’) on cell growth and signalling were evaluated in four ovarian cancer cell lines (PE01, PE04, SKOV-3, OVCAR-5) that
express the epidermal growth factor receptor, and in A2780, which is epidermal growth factor receptor-negative.
Transforming growth factor-a stimulated growth was completely inhibited by concentrations of ZD 1839 50.3 mM in the
epidermal growth factor receptor-expressing cell lines, as were transforming growth factor-a stimulated phosphorylation of the
epidermal growth factor receptor and downstream components of the MAP kinase and PI-3 kinase signalling cascades.
Growth inhibition in the absence of added transforming growth factor-a was also observed which could be consistent with
suppression of action of autocrine epidermal growth factor receptor-activating ligands by ZD 1839. In support of this,
transforming growth factor-a, EGF and amphiregulin mRNAs were detected by RT – PCR in the epidermal growth factor
receptor-expressing cell lines. ZD 1839 inhibited growth of the PE04 ovarian cancer xenograft at 200 mg kg71 day71. These
data lend further support to the view that targeting the epidermal growth factor receptor in ovarian cancer could have
therapeutic benefit.
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The epidermal growth factor receptor (EGFR) is a 170 kDa trans-
membrane glycoprotein that contains an external binding domain
and an intracellular tyrosine kinase domain. It mediates the mito-
genic response to the EGF family of ligands which includes both
EGF and transforming growth factor-a (TGFa) (Carpenter,
1987). Ligand binding activates the EGFR by inducing either
homodimerization or heterodimerization with other members of
the ErbB receptor family (ErbB2, ErbB3 and ErbB4) (Olayioye et
al, 2000). Upon dimerization, key autophosphorylation events
occur on C-terminal tyrosine residues of the intracellular domain
which provide high-affinity docking sites for a series of transducing
molecules that transmit the mitogenic signal to the nucleus. Signal-
ling cascades such as the Ras/Raf/ERK/MAPK pathway (Egan and
Weinberg, 1993), PI-3K/AKT pathway (Verbeek et al, 1998) and
the PLCg pathway (Chen et al, 1994) have all been implicated as
routes to gene activation or more direct modulators of mitogenesis
and other cancer-promoting phenotypes.
The EGFR is reported to be present in between 33 and 75% of
ovarian cancers (Berchuck et al, 1991; Morishige et al, 1991) and
has been implicated in both the growth and progression of this
disease. Ovarian cancers that express increased concentrations of
the EGF receptor are associated with poor survival (Berchuck et al,
1991; Bartlett et al, 1996) and both TGFa and EGF have been shown
to stimulate growth of ovarian cancer cells in culture (Morishige et al,
1991; Crew et al, 1992). Studies utilizing NIH 3T3 cells have indi-
cated that overexpression of EGFR in the presence of a stimulatory
ligand is sufficient to confer cancer phenotypes (Verbeek et al,
1998). Evidence for both autocrine and paracrine regulation of
growth by TGFa/EGFR activation has been obtained in this disease
(Morishige et al, 1991; Stromberg et al, 1992).
Given the importance of this receptor in both ovarian cancer
growth and progression, it represents a good target for anticancer
drug development. A variety of strategies to block activation of the
receptor have been developed and these include use of anti-EGFR
blocking monoclonal antibodies and EGFR-targeted tyrosine kinase
inhibitors.
In the present study we have explored the potential of a new
EGFR targeted tyrosine kinase inhibitor (ZD 1839, ‘Iressa’) to inhi-
bit growth of ovarian cancer. Enzymatic activity of the intracellular
tyrosine kinase domain of the EGFR is essential for signal transduc-
tion (Chen et al, 1987) and a number of specific and potent
inhibitors of the EGF receptor have been identified (Fry et al,
1994; Levitzki and Gazit, 1995; Wakeling et al, 1996). We have
previously demonstrated that one of these inhibitors, ZM 252868
(PD 153035, 4(3-bromoanilino)-6,7-dimethoxyquinazoline) inhib-
ited ovarian cancer cell growth and tyrosine phosphorylation on
the EGFR (Simpson et al, 1999), however this compound was inef-
fective in vivo (Kunkel et al, 1995). A related structure, ZD 1839,
has been developed which is not only a potent and selective inhi-
bitor of the EGFR tyrosine kinase but has demonstrated excellent
growth inhibitory activity after oral administration (Woodburn et
al, 1997; Ciardiello et al, 2000). The drug is currently under clinical
evaluation in several Phase I – III trials in cancer patients (Baselga
et al, 2000; Ferry et al, 2000). In the present study we have tested
its activity against five ovarian cancer cell lines in vitro to assess its
growth inhibitory activity and its ability to inhibit TGFa activated
EGFR phosphorylation in this disease. We have also assessed its
ability to inhibit growth of an ovarian cancer xenograft growing
in nude mice.
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MATERIALS AND METHODS
Cell lines
The human ovarian carcinoma cell lines used were; PE01 and PE04
(Langdon et al, 1988), SKOV-3 and A2780 (European Collection of
Animal Cell Cultures, Porton Down, UK), and OVCAR-5 (kindly
provided by Dr T Hamilton, Fox Chase Institute,
PA, USA). All lines were routinely cultured at 378C in a
humidified atmosphere of 5% CO2 in air, using ‘full media’; RPMI
1640 containing phenol red (Gibco BRL, Paisley, UK) supplemen-
ted with 10% heat-inactivated foetal calf serum (FCS),
L-glutamine (2 mM), penicillin (100 IU ml71) and streptomycin
(100 mg ml71).
Growth assays
Log-phase cells were trypsinized and seeded in full media into 24-
well plates (Falcon) in quadruplicate at densities between 0.5 –
2.56104 cells per well71. After 24 h media was replaced (following
two phosphate-buffered saline (PBS) washes) with phenol red free
RPMI 1640 (PRF-RPMI) containing 5% double charcoal-stripped
foetal calf serum, penicillin (100 U ml71), streptomycin
(100 mg ml71), glutamine (2 mM). After a further 24 h, drugs
and fresh media were added to cells in PRF-RPMI 1640; designated
day 0. Tyrosine kinase inhibitor ZD 1839 was added 30 min prior
to the addition of TGFa (1 nM). Drugs and media were replaced
on day 2, then cells harvested on day 5 and counted using a Coul-
ter counter (Coulter Electronics Ltd., Luton, UK).
Western blotting
Cell lines were seeded in full media into 60 cm2 petri dishes
(Nunclon). After 24 h, cells were washed twice with PBS before
adding PRF-RPMI. A further 24 h later, (cells 60 – 80% conflu-
ent) plates were treated for 30 min with PRF-RPMI media in
the presence or absence of ZD 1839 (0.03 – 3.0 mM). Media
+ZD 1839 was then replenished and incubated for a further
15 min in the presence or absence of TGFa (1 nM). Cells were
washed twice in ice cold PBS, and lysed using 1 ml hypotonic
lysis buffer (50 mM Tris-HCl (pH 7.5), 5 mM EGTA (pH 8.5),
150 mM NaCl, 1% Triton X-100, 2 mM sodium orthovanadate,
50 mM sodium fluoride, 20 mM phenylarsine oxide, 1 mM phenyl-
methanesulfonylfluoride, 10 mg ml71 leupeptin, 10 mg ml71
aprotinin and 10 mM sodium molybdate). Lysates were clarified
by centrifugation for 6 min at 13 000 r.p.m. in a microfuge at
48C. Total protein concentrations of supernatants were deter-
mined using a Bio-rad protein Assay Kit (Bio-rad, Richmond,
CA, USA).
Samples (35 – 75 mg) were denatured at 958C for 5 min in
buffer containing SDS and mercaptoethanol and resolved by
7.5% SDS – PAGE. They were transferred onto Immobilon-P
membranes (Millipore, Bedford, MA, USA) overnight at 48C.
After transfer, membranes were blocked with 1% blocking
reagent (containing 10% purified casein protein in maleic acid,
Boehringer Mannheim) diluted in TBS (Tris buffered saline;
20 mM Tris-HCl, 137 mM NaCl, pH 7.5) for 1 h at room
temperature. Primary antibodies were added in 0.5% TBS/block-
ing solution and left overnight at 48C; EGFR (Neomarkers Ab12)
1/200, phosphotyrosine (Santa Cruz PY20) 1/200, phospho-ERK
(NEB 9101) 1/1000 and phospho-AKTS473 (NEB 9271) 1/1000.
Membranes were then washed; 365 min TBS-T (TBS with
0.1% Tween 20), and 265 min in 0.5% TBS/blocking solution,
then incubated with appropriate secondary antibody for 1 h at
room temperature. Membranes were washed again; 365 min
with TBS-T, 365 min with TBS. After 1 min incubation in
room temperature luminescence substrate solution, light emission
was detected on X-ray film.
RT – PCR
Total cellular RNA was extracted from cells in log phase growth
using TRI reagentTM (Sigma, Poole, UK). Samples were treated
with 20 U/50 ml DNAse 1 (Boehringer Mannheim, East Sussex,
UK) to remove genomic DNA contamination. RNA was then re-
extracted using a phenol/chloroform protocol. Reverse transcrip-
tion was performed with a first strand cDNA Synthesis kit
(Boehringer Mannheim) using the oligo dT primer provided.
RNA (1 mg) yielded 20 ml of cDNA of which 2 ml was used for each
subsequent PCR reaction with each primer pair (Table 1). PCR
reactions (20 ml) contained: 16buffer, 1.5 mM MgCl2, 0.2 mM
dNTP mixture, 1.0 U Taq polymerase (ICRF, Clare Hall, South
Mimms, UK), 500 nM each primer (ICRF). RNA which had not
been reverse transcribed was used in PCR reactions to check for
genomic contamination of RNA samples.
Xenograft experiments
The PE04 xenograft was initiated from the cultured PE04 ovarian
cancer cell line and maintained subcutaneously in the flanks of
female nude mice. Animals were at least 8 weeks old at the time
of experimentation and were maintained in negative pressure isola-
tors (La Calhene, UK). For experiments, tumour fragments were
implanted and allowed to develop to 4 – 6 mM (period of approxi-
mately 1 month). Animals were then allocated to treatment (five
mice per group) or control (10 mice per group) groups and treat-
ment commenced (defined as day 0).
Treatment groups contained 8 – 10 tumours and control groups
14 – 18 tumours. The drug was given orally as a suspension in 0.5%
polyoxyethylenesorbitan (Tween 80) for 14 days. Tumour size was
measured twice weekly using calipers and the volume calculated
according to the formula: p/66length6width2. Relative tumour
volumes were then calculated for each individual tumour by dividing
the tumour volume on day t (Vt) by the tumour volume on day 0 (V0)
and multiplying by 100. Body weight changes were monitored every 4
days to monitor toxicity. All experiments were conducted according
to UKCCCR (1998) guidelines under a Home Office licence.
Statistical analysis
The Student t-test was used to compare differences between
groups.
RESULTS
The tyrosine kinase inhibitor ZD 1839 inhibits TGFa
stimulated growth of ovarian cancer cells in vitro
Five ovarian cancer cell lines (PE01, PE04, SKOV-3, OVCAR-5 and
A2780) were investigated for their response to the EGFR-targeted
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Table 1 PCR primers used
PCR primers
Product
size (bp)
EGF-R Antisense 5’-CACATCTCCATCACTTATCTCCC-3’ 516
Sense 5’-ACCTGCGTGAAGAAGTGTCC-3’
g-Actin Antisense 5’-ACGAGACCACCTTCAACTCC-3’ 474
Sense 5’-CAAGTTCTACAATCCAGTGC-3’
TGF-a Sense 5’-CGCTCTGGGTA TTGTGTTGG-3’ 666
Antisense 5’-GGTCCGCTGA TTTCTTCTCT-3’
EGF Sense 5’-AGGGAAGATGAC CACCACTATTCC-3’ 316
Antisense 5’-TTTTCGATAGCAGCTTCTGAGTCC-3’
Amphiregulin Sense 5’-GTTAAGCCCCCCCAAAACAAGACG-3’ 397
Antisense 5’-TTTCTTTCGTTCCTCAGCTTCTCC-3’
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inhibitor ZD 1839. Expression levels of EGFR vary widely in this
series of cell lines, with A2780 indicating a very weak EGFR mRNA
band and no visible protein, PE04 and PE01 expressing only low
levels, SKOV-3 intermediate levels and OVCAR-5 the highest level
of EGFRs (Figure 1). We have previously demonstrated expression
of the EGF receptor in PE01 and PE04 cells using ligand binding
and immunofluorescence techniques (Crew et al, 1992). The five
cell lines were treated with ZD 1839 for 5 days in the presence
or absence of 1 nm TGFa and growth response was assessed. Addi-
tion of 1 nM TGFa produced an approximately 450% increase in
PE01 cell number, a 67% increase for PE04 and an increase of
20 – 30% in the SKOV-3 and OVCAR-5 cell lines. This increase
was abolished by ZD 1839 at concentrations 50.3 mM in these four
cell lines with partial reversal at concentrations of 0.03 to 0.1 mM
(Figure 2). In the absence of TGFa, ZD 1839 inhibited growth of
PE01 cells at concentrations 50.03 mM, SKOV-3 cells at concentra-
tions 50.3 mM and PE04 cells at 3 mM (Figure 2). The A2780 cell
line showed no growth stimulation by TGFa and minimal growth
effects (0, 6 and 19% inhibition at 0.3, 1 and 3 mM ZD 1839
respectively) in response to ZD 1839 (data not shown). Growth
inhibition in the other cell lines was up to approximately 50% of
control cell number and may reflect the presence of endogenous
TGFa or other EGFR-activating ligands. To test this possibility of
autocrine regulation, the presence of TGFa, EGF and amphiregulin
in the cell lines were sought by the use of RT – PCR. All four
TGFa-responsive cell lines were found to express mRNAs for these
three growth factors, indicating the potential for autocrine regula-
tion, whereas A2780 was negative (Figure 3).
Inhibition of tyrosine phosphorylation of the EGFR by
ZD 1839
The cell lines were pre-treated with ZD 1839 for 30 min before a
15 min incubation in the presence or absence of 1 nM TGFa.
TGFa increased tyrosine phosphorylation of both the EGFR
and ErbB2 in the four responsive cell lines (PEO1, PEO4,
SKOV-3 and OVCAR-5) consistent with ligand activation via
the EGFR and heterodimerization with ErbB2 (Figure 4A).
A2780 showed no band for either EGFR or ErbB2. The identity
of bands had been confirmed in previous experiments using anti-
bodies specific for the EGFR and erbB2 (data not shown). At
concentrations of ZD 1839 40.3 mM, the EGFR phosphorylation
was completely blocked in all cell lines except OVCAR-5 in
which EGFR phosphorylation was blocked at concentrations of
ZD 1839 41 mM. The ErbB2 phosphorylation was also decreased
but to a lesser degree in all four responsive lines (Figure 4A). In
the absence of TGFa, only ErbB2 phosphorylation was observed
in untreated cells (Figure 4A). This was also decreased after
addition of ZD 1839 but only at higher concentrations of inhi-
bitor.
Inhibition of the ERK and PI3-kinase pathways by ZD 1839
Lysates of the five cell lines were also probed with antibodies recog-
nizing phospho-ERK, a member of the MAP kinase cascade, and to
phospho-AKTS473, downstream of PI-3 kinase. TGFa increased
phosphorylation of both ERK 1 and 2 (p44 and p42) in the four
responsive cell lines, but not in A2780 (Figure 4B). ZD 1839
blocked ERK phosphorylation at 1 and 3 mM, reflecting the results
for EGFR and erbB2 tyrosine phosphorylation (Figure 4A). A simi-
lar result was obtained for phospho-AKT, with the four responsive
lines showing phosphorylation induced by TGFa, which was
blocked in all but the SKOV-3 cell line at the lower concentration
of 0.3 mM ZD 1839. Both phospho-ERK and phospho-AKT were
elevated at basal conditions in A2780 cells compared to the other
cell lines and neither TGFa nor ZD 1839 had any effect on expres-
sion (Figure 4B,C).
Inhibition of the PE04 ovarian cancer xenograft by
ZD 1839
The ability of ZD 1839 to inhibit growth in vivo was assessed using
the PE04 ovarian cancer model. Previous xenograft studies have
used ZD 1839 at doses of 150 – 250 mg kg71 day71 (Ciardiello
et al, 2000; Sirotnak et al, 2000). ZD 1839 when given orally
at 200 mg kg71 day71 for 14 days produced 450% inhibition
of control growth at the end of the treatment period, and this
effect persisted for a further 31 days, at which point the experiment
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B. EGF receptor mRNA
PE
01
PE
04
SK
OV
-3
OV
CA
R-5
A2
78
0
-p170 (EGFR)
-p42 ( g -actin)
EGFR
g -actin
PE
01
PE
04
SK
OV
-3
OV
CA
R-5
A2
78
0
Figure 1 Western blot and RT – PCR analyses of the EGFR in ovarian cancer cell lines. The PE01, PE04, SKOV-3, OVCAR-5 and A2780 ovarian cancer
cell lines were subjected to (A) Western blot analysis using antibodies targeting the EGFR and actin or (B) RT – PCR using primers specific for either the
EGFR or g-actin as described in Materials and Methods.
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was terminated (Figure 5). A lower dose, 50 mg kg71 day71
produced a small effect with statistical significance at day 17 (i.e.
immediately after the full treatment course) but this effect did
not persist (Figure 5). The effect of continued treatment at either
dose was not evaluated. At 50 mg kg71 day71 there was no mean
body weight loss compared to control at end of treatment (day 14)
and after a further 14 days (day 28) while at 200 mg kg71 day71
there was a small mean weight loss (9.8+1.6% on day 14 and
10.9+4.5% on day 28).
DISCUSSION
Strategies targeting the EGFR may well have therapeutic potential
in ovarian cancer as the receptor is frequently overexpressed in
this disease and patients with tumours expressing high levels of
EGFR tend to have a poor prognosis. ZD 1839 is one of the
latest inhibitors developed against this receptor and, in addition
to being both potent and selective, it is orally active. This is the
first detailed study of ZD 1839 in a range of ovarian cancer cell
lines and our results extend the previous observations of broad
spectrum activity for this agent against a range of xenograft types
including cancers of the lung, colon, prostate and vulva (Ciar-
diello et al, 2000; Sirotnak et al, 2000). We observed good
reversal of EGFR tyrosine phosphorylation produced by TGFa
activation in ovarian cancer cell lines and this was consistent
with growth inhibition at these concentrations. In the absence
of added TGFa, the cell lines were shown to produce mRNAs
for several EGFR-activating ligands indicating the strong possibi-
lity of autocrine regulation. Under these conditions, ZD 1839
partially inhibited growth of several of the cell lines consistent
with blockade of activation via this endogenous expression.
Extension into a xenograft model confirmed the activity of the
drug given orally to the PE04 ovarian cancer in vivo. We have
previously investigated the activity of another anilinoquinazoline,
ZM 252868 (PD 153035) which had similar in vitro properties to
those of ZD 1839; however its activity in vivo was limited and
while it demonstrated transient reduction of EGFR tyrosine
phosphorylation in A431 xenografts, this was insufficient to
produce in vivo growth inhibition (Kunkel et al, 1996). ZD
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Figure 2 Effect of ZD 1839 on the basal and TGFa-stimulated growth of the PE01, PE04, SKOV-3 and OVCAR-5 ovarian cancer cell lines. ZD 1839
added in the absence or presence of TGFa (1 nM). Statistically significant differences: ** control vs control + TGFa=P50.05; Student t-test ; *test vs appro-
priate control=P50.05, Student t-test.
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Figure 3 RT – PCR analysis of EGFR activating ligands in ovarian cancer
cell lines. mRNAs from the PE01, PE04, SKOV-3, OVCAR-5 and A2780 cell
lines were reverse transcribed. Use of specific primers for TGFa, EGF,
amphiregulin and g-actin allowed specific amplification of these cDNAs
as described in Materials and Methods.
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Figure 4 Western blot of ZD 1839 treated cell lines using (A) the anti-phosphotyrosine PY20 antibody, (B) the phospho-ERK NEB 9101 antibody and
(C) the phospho-AKTS473 NEB 9271 antibody. Blots are shown for the PE01, PE04, SKOV-3, OVCAR-5 and A2780 cell lines. ZD 1839 was added 30 min
prior to TGFa (1 nM) addition and lysates were collected after 15 min exposure to TGFa. Amounts of protein loaded were 75 mg lane71 for the phos-
photyrosine gel and 35 mg for the phospho-ERK and phospho-AKT gels. Exposure times varied from 20 s to 2 min but were the same for each antibody.
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Figure 5 Effect of ZD 1839 on the growth of established PE04 xenograft grown in nude mice. Groups of nude mice received either vehicle only or daily
oral treatment of ZD 1839 at either 200 mg kg71 day71 or 50 mg kg71 day71. Points shown are mean values for groups of 5 – 8 tumours. Error bars=
standard deviation. Statistically significant differences from control: *P50.05, Student t-test.
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1839 possesses significant in vivo activity and is now being eval-
uated in clinical trials.
Western blot probing for tyrosine phosphorylation confirmed
that ZD 1839 was acting as predicted, with the inhibitor targeting
the EGFR and having a secondary effect on ErbB2 phosphorylation.
The latter is likely to be due to inhibition of heterodimer phos-
phorylation. Furthermore, the same concentrations of ZD 1839
shown to inhibit receptor activation were associated with growth
inhibition. Phosphorylation events in the downstream effector
molecules of the MAP kinase (phospho-ERK) and PI-3 kinase
(phospho-AKT) pathways revealed some of the complexity
involved with signal transduction from these receptors. There was
a striking similarity between phosphorylation and hence activation
of the ErbB receptors in response to both TGFa stimulation and
receptor blockade, and events in the downstream signalling
cascades. Phosphorylation profiles of ERK and AKT over the
concentration ranges closely resembled that of the two ErbB recep-
tors over the concentration ranges and was consistent with both
signalling cascades being induced as a consequence of receptor acti-
vation. It is likely that signalling via one or both of the pathways
leads to the mitogenic effect seen upon TGFa stimulation, and
hence its loss upon blockade.
In addition to the strategy investigated here, we have previously
shown that antibody blockade of the EGFR produces similar
growth reversing effects in the PE01 cell line (Simpson et al,
1998). The use of antibodies to target the EGFR is well advanced
in clinical trials and a humanized/mouse chimeric monoclonal
antibody 225 is undergoing evaluation.
Promising clinical results in head and neck cancer have been
obtained when EGFR inhibition has been combined with radio-
therapy or chemotherapy (Ezekial et al, 1999; Mendelsohn et al,
1999). It is likely that other EGFR targeting strategies might opti-
mally be used in combination with other drugs. To this end,
combination of ZD 1839 with a range of cytotoxics have already
produced interesting results in a range of tumour types in vitro
and in vivo (Ciardiello et al, 2000; Sirotnak et al, 2000). Among
the cell lines tested in vitro was the OVCAR-3 ovarian cancer cell
line; supra-additive effects were observed for ZD 1839 in combina-
tion with cisplatin, carboplatin paclitaxel and docetaxel (Ciardiello
et al, 2000).
In the clinical setting, it will be important to define tumours
whose growth is dependent on the EGFR and which are being
driven by activating ligands such as TGFa and EGF. It is apparent
from these data that levels of EGFR protein expression are not
simply associated with magnitude of ligand response as even cell
lines with low levels of EGFR can show a marked stimulation when
treated with TGFa. However, tyrosine phosphorylation of the
EGFR in clinical specimens of ovarian cancer can be readily iden-
tified and it seems likely that those tumours in which activation is
found represent the target population for these agents.
In conclusion, these data indicate that the EGFR-targeted tyro-
sine kinase inhibitor ZD 1839 can inhibit growth of ovarian
cancer cells in vitro and in vivo, consistent with inhibition of tyro-
sine phosphorylation at the EGFR. These results lends further
support to the view that targeting the EGFR in ovarian cancer
could have therapeutic value.
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